Invivyd says LIBERTY Phase 3 trial shows VYD2311 safety, tolerability top mRNA COVID-19 vaccine

• Invivyd reported positive topline Phase 3 LIBERTY results for VYD2311, already released, showing better safety and tolerability than an mRNA COVID-19 vaccine.
• Co-administration with an mRNA vaccine showed no sign of reducing vaccine-driven immune response, while increasing overall neutralizing activity.
• The company plans to use LIBERTY with the ongoing DECLARATION pivotal study to support a U.S. BLA filing under FDA accelerated approval.
• DECLARATION topline safety and immunogenicity results are expected in October, with clinical efficacy data planned to be unblinded post-approval if granted.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invivyd Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609290701PRIMZONEFULLFEED9835498) on September 29, 2026, and is solely responsible for the information contained therein.